Chronic lymphocytic leukemia: New concepts and emerging therapies

Current Treatment Options in Oncology

Volumn 10, Issue 1-2, 2009, Pages 16-32

  Ahmadi, Tahamtan ^a   Maniar, Tapan ^a   Schuster, Stephen ^a   Stadtmauer, Edward ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABT 263; ALEMTUZUMAB; ALKYLATING AGENT; ALLOPURINOL; ANTINEOPLASTIC AGENT; BENDAMUSTINE; BETA 2 MICROGLOBULIN; CD23 ANTIGEN; CD38 ANTIGEN; CHLORAMBUCIL; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLAVOPIRIDOL; FLUDARABINE; LENALIDOMIDE; LUMILIXIMAB; MITOXANTRONE; OBLIMERSEN; OFATUMUMAB; PENTOSTATIN; PREDNISOLONE; PROTEIN KINASE ZAP 70; RITUXIMAB; THYMIDINE KINASE; UNCLASSIFIED DRUG; VINCRISTINE;

ALLOGENEIC STEM CELL TRANSPLANTATION; ANEMIA; ANTINEOPLASTIC ACTIVITY; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RELAPSE; CANCER STAGING; CANCER SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; DISEASE MARKER; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG CLEARANCE; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG DOSE SEQUENCE; DRUG EFFICACY; DRUG FATALITY; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; FATIGUE; HUMAN; HYDRATION; INFECTION; LEUKOPENIA; LOW DRUG DOSE; LYMPHOCYTOMA; MANTLE CELL LYMPHOMA; MINIMAL RESIDUAL DISEASE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; NONHODGKIN LYMPHOMA; OPTIMAL DRUG DOSE; PROGNOSIS; PROTEIN EXPRESSION; RECOMMENDED DRUG DOSE; REDUCED INTENSITY CONDITIONING; REVIEW; SALVAGE THERAPY; THROMBOCYTOPENIA; TREATMENT INDICATION; TREATMENT PLANNING; TREATMENT RESPONSE; TUMOR FLARE; TUMOR LYSIS SYNDROME; UNSPECIFIED SIDE EFFECT; VOMITING;

ANTIBODIES, MONOCLONAL; ANTIGENS, CD5; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; B-LYMPHOCYTE SUBSETS; DISEASE PROGRESSION; DRUGS, INVESTIGATIONAL; HUMANS; IMMUNOLOGIC FACTORS; IMMUNOTHERAPY; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MULTICENTER STUDIES AS TOPIC; NEOPLASM, RESIDUAL; NITROGEN MUSTARD COMPOUNDS; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SALVAGE THERAPY;

EID: 70149110428     PISSN: 15272729     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11864-008-0079-8     Document Type: Review

References (99)

1. Jemal, A., et al., 2006. Cancer statistics, 2006. CA Cancer J Clin, 56(2):106-130.
2. Dameshek, W., 1967. Chronic lymphocytic leukemia-an accumulative disease of immunolgically incompetent lymphocytes. Blood, 29(Suppl 4):566-584.
3. Messmer, B.T., et al. 2005 In vivo measurements document the dynamic cellular kinetics of chronic lymphocytic leukemia B cells. J Clin Invest 115(3):755-764.
4. Fais, F., et al. 1998 Chronic lymphocytic leukemia B cells express restricted sets of mutated and unmutated antigen receptors. J Clin Invest 102(8):1515-25. doi: 10.1172/JCI3009
5. Damle, R.N., et al. 2002 B-cell chronic lymphocytic leukemia cells express a surface membrane phenotype of activated, antigen-experienced B lymphocytes. Blood. 99(11):4087-93. doi: 10.1182/blood.V99.11.4087
6. Stevenson, F.K. and F. Caligaris-Cappio (2004) Chronic lymphocytic leukemia: Revelations from the B-cell receptor. Blood 103(12):4389-95. doi: 10.1182/blood-2003-12-4312
7. Kipps, T.J., et al. 1989 Developmentally restricted immunoglobulin heavy chain variable region gene expressed at high frequency in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A 86(15):5913-7. doi: 10.1073/pnas.86.15.5913
8. Stamatopoulos, K., et al. 2007 Over 20% of patients with chronic lymphocytic leukemia carry stereotyped receptors: Pathogenetic implications and clinical correlations. Blood 109(1):259-70. doi: 10.1182/blood-2006-03-012948
9. Murray, F., et al. 2008 Stereotyped patterns of somatic hypermutation in subsets of patients with chronic lymphocytic leukemia: Implications for the role of antigen selection in leukemogenesis. Blood 111(3):1524-33. doi: 10.1182/blood-2007-07-099564
10. Bofill, M., et al. 1985 Human B cell development II Subpopulations in the human fetus. J Immunol 134(3):1531-8.
11. Gadol, N. and K.A. Ault 1986 Phenotypic and functional characterization of human Leu1 (CD5) B cells. Immunol Rev 93:23-34. doi: 10.1111/ j.1600-065X.1986.tb01500.x
12. Granziero, L., et al. 2001 Survivin is expressed on CD40 stimulation and interfaces proliferation and apoptosis in B-cell chronic lymphocytic leukemia. Blood 97(9):2777-83. doi: 10.1182/blood.V97.9.2777
13. Soma, L.A., F.E. Craig, and S.H. Swerdlow 2006 The proliferation center microenvironment and prognostic markers in chronic lymphocytic leukemia/ small lymphocytic lymphoma. Hum Pathol 37(2):152-9. doi: 10.1016/ j.humpath.2005.09.029
14. Plater-Zyberk, C., et al. 1985 A rheumatoid arthritis B cell subset expresses a phenotype similar to that in chronic lymphocytic leukemia. Arthritis Rheum 28(9):971-6.doi: 10.1002/art.1780280903
15. Kay, N.E. 1981 Abnormal T-cell subpopulation function in CLL: Excessive suppressor (T gamma) and deficient helper (T mu) activity with respect to B-cell proliferation. Blood 57(3):418-20.
16. Platsoucas, C.D., et al., 1982 Abnormal T lymphocyte subpopulations in patients with B cell chronic lymphocytic leukemia: An analysis by monoclonal antibodies. J Immunol 129(5):2305-12.
17. Seiler, T., H. Dohner, and S. Stilgenbauer 2006 Risk stratification in chronic lymphocytic leukemia. Semin Oncol. 33(2):186-94. doi: 10.1053/ j.seminoncol.2006.01.017
18. Dohner, H., et al., 2000 Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 343(26):1910-6. doi: 10.1056/ NEJM200012283432602
19. Montillo, M., et al., 2005 Chronic lymphocytic leukemia: Novel prognostic factors and their relevance for risk-adapted therapeutic strategies. Haematologica. 90(3):391-9.
20. Hamblin, T.J., et al., 1999 Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 94(6):1848-54.
21. Damle, R.N., et al., 1999 Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 94(6):1840-7.
22. Tobin, G. and R. Rosenquist 2005 Prognostic usage of V(H) gene mutation status and its surrogate markers and the role of antigen selection in chronic lymphocytic leukemia. Med Oncol 22(3):217-28. doi: 10.1385/ MO:22:3:217
23. Rassenti, L.Z., et al., 2004 ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia. N Engl J Med 351(9):893-901. doi: 10.1056/NEJMoa040857
24. Del Principe, M.I., et al., 2006 Clinical significance of ZAP-70 protein expression in B-cell chronic lymphocytic leukemia. Blood 108(3):853-61. doi: 10.1182/blood-2005-12-4986
25. Rosenwald, A., et al., 2001 Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia. J Exp Med 194(11):1639-47. doi: 10.1084/jem.194.11.1639
26. Hallek, M., et al., 1999 Elevated Serum Thymidine Kinase Levels Identify a Subgroup at High Risk of Disease Progression in Early, Nonsmoldering Chronic Lymphocytic Leukemia. Blood 93(5):1732-1737.
27. Molica, S., et al., 1996 Cellular expression and serum circulating levels of CD23 in B-cell chronic lymphocytic leukemia Implications for prognosis. Haematologica 81(5):428-33.
28. Hallek, M., et al., 1996 Serum beta(2)-microglobulin and serum thymidine kinase are independent predictors of progression-free survival in chronic lymphocytic leukemia and immunocytoma. Leuk Lymphoma 22(5-6):439-47. doi: 10.3109/10428199609054782
29. Molica, S., et al., 1999 Clinico-prognostic implications of simultaneous increased serum levels of soluble CD23 and beta2-microglobulin in B-cell chronic lymphocytic leukemia. Eur J Haematol. 62(2):117-22.
30. Tam, C.S., et al., 2008 Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia. Blood 112(4):975-80. doi: 10.1182/ blood-2008-02-140582
31. Thurmes, P., et al., 2008 Comorbid conditions and survival in unselected, newly diagnosed patients with chronic lymphocytic leukemia. Leuk Lymphoma 49(1):49-56. doi: 10.1080/10428190701724785
32. Molica, S. and D. Levato 2001 What is changing in the natural history of chronic lymphocytic leukemia? Haematologica 86(1):8-12.
33. Chemotherapeutic options in chronic lymphocytic leukemia: A meta-analysis of the randomized trials 1999 CLL Trialists' Collaborative Group. J Natl Cancer Inst 91(10):861-8. doi: 10.1093/jnci/91.10.861
34. Cheson, B.D., et al., 1988 Guidelines for clinical protocols for chronic lymphocytic leukemia: Recommendations of the National Cancer Institute-sponsored working group. Am J Hematol 29(3):152-63. doi: 10.1002/ajh.2830290307
35. Cheson, B.D., et al., 1996 National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: Revised guidelines for diagnosis and treatment. Blood 87(12):4990-7.
36. Hallek, M., et al., 2008 Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: A report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 111(12):5446-56.
37. Shanafelt, T.D., S.M. Geyer, and N.E. Kay, 2004 Prognosis at diagnosis: integrating molecular biologic insights into clinical practice for patients with CLL. Blood 103(4):1202-10. doi: 10.1182/blood-2003-07-2281
38. Bergmann M, Busch R, Hallek M: Elevated thymidine kinase and short lymphocyte doubling time in combination with unfavourable cytogenetics or unmutated IgVH status are strong predictors for high individual risk for rapid disease progression in patients with B-CLL in Binet stage A: an interim report from the CLL1 protocol of the German CLL Study Group (GCLLSG). Blood 102: Abstr 2464
39. Johnson, S., et al. 1996 Multicentre prospective randomised trial of fludarabine versus cyclophosphamide, doxorubicin, and prednisone (CAP) for treatment of advanced-stage chronic lymphocytic leukaemia The French Cooperative Group on CLL. Lancet 347(9013):1432-8.
40. Rai, K.R., et al., 2000 Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N Engl J Med 343(24):1750-7. doi: 10.1056/NEJM200012143432402
41. Leporrier, M., et al., 2001 Randomized comparison of fludarabine, CAP, and ChOP in 938 previously untreated stage B and C chronic lymphocytic leukemia patients. Blood 98(8):2319-25. doi: 10.1182/blood.V98.8.2319
42. Eichhorst, B.F., et al., 2006 Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia. Blood 107(3):885-91. doi: 10.1182/ blood-2005-06-2395
43. Flinn, I.W., et al., 2007 Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997. J Clin Oncol 25(7):793-8. doi: 10.1200/JCO.2006.08.0762
44. Grever, M.R., et al., 2007 Comprehensive assessment of genetic and molecular features predicting outcome in patients with chronic lymphocytic leukemia: Results from the US Intergroup Phase III Trial E2997. J Clin Oncol 25(7):799-804. doi: 10.1200/JCO.2006.08.3089
45. Knauf, W.U., et al., 2007 Bendamustine Versus Chlorambucil in Treatment-Naive Patients with B-Cell Chronic Lymphocytic Leukemia (B-CLL): Results of an International Phase III Study. ASH Annual Meeting Abstracts 110(11):2043
46. Hale, G., et al. 1990 The CAMPATH-1 antigen (CDw52). Tissue Antigens 35(3):118-27. doi: 10.1111/j.1399-0039.1990.tb01767.x
47. Keating, M.J., et al. 2002 Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: Results of a large international study. Blood 99 (10):3554-61. doi: 10.1182/ blood.V99.10.3554
48. Lundin, J., et al. 2002 Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL). Blood 100(3):768-73. doi: 10.1182/blood-2002-01-0159
49. Hillmen, P., et al. 2007 Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia. J Clin Oncol 25(35):5616-23. doi: 10.1200/JCO.2007.12.9098
50. Flynn, J.M. and J.C. Byrd 2007 Have we forgotten the purpose of phase III studies? J Clin Oncol 25(35):5553-5. doi: 10.1200/JCO.2007.13.7810
51. McLaughlin, P., et al. 1998 Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program. J Clin Oncol 16(8):2825-33.
52. Huhn, D., et al. 2001 Rituximab therapy of patients with B-cell chronic lymphocytic leukemia. Blood 98(5):1326-31. doi: 10.1182/blood.V98.5.1326
53. Manshouri, T., et al. 2003 Circulating CD20 is detectable in the plasma of patients with chronic lymphocytic leukemia and is of prognostic significance. Blood 101(7):2507-13. doi: 10.1182/blood-2002-06-1639
54. Byrd, J.C., et al. 2001 Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity. J Clin Oncol 19(8):2153-64.
55. O'Brien, S.M., et al. 2001 Rituximab dose-escalation trial in chronic lymphocytic leukemia. J Clin Oncol 19(8):2165-70.
56. Byrd, J.C., et al. 2003 Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: Results from Cancer and Leukemia Group B 9712 (CALGB 9712). Blood 101(1):6-14. doi: 10.1182/blood-2002-04-1258
57. Keating, M.J., et al. 2005 Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol 23(18):4079-88. doi: 10.1200/ JCO.2005.12.051
58. Kay, N.E., et al. 2007 Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia. Blood 109 (2):405-11. doi: 10.1182/blood-2006-07-033274
59. Byrd, J.C., et al 2005, Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: An updated retrospective comparative analysis of CALGB 9712 and CALGB 9011. Blood 105(1):49-53. doi: 10.1182/blood-2004-03-0796
60. Wierda, W.G., et al. 2007 Combined Cyclophosphamide, Fludarabine, Alemtuzumab, and Rituximab (CFAR), an Active Frontline Regimen for High-Risk Patients with CLL. ASH Annual Meeting Abstracts 110(11):628
61. Rawstron, A.C., et al. 2007 International standardized approach for flow cytometric residual disease monitoring in chronic lymphocytic leukaemia. Leukemia 21(5):956-64.
62. Moreton, P., et al. 2005 Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival. J Clin Oncol 23(13):2971-9. doi: 10.1200/JCO.2005.04.021
63. Wendtner, C.M., et al. 2004 Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission-experience on safety and efficacy within a randomized multicenter phase III trial of the German CLL Study Group (GCLLSG). Leukemia 18 (6):1093-101. doi: 10.1038/sj.leu.2403354
64. Nabhan, C., S. Coutre, and P. Hillmen 2007 Minimal residual disease in chronic lymphocytic leukaemia: Is it ready for primetime? Br J Haematol 136(3):379-92. doi: 10.1111/j.1365-2141.2006.06428.x
65. O'Brien, S.M., et al. 2003 Alemtuzumab as treatment for residual disease after chemotherapy in patients with chronic lymphocytic leukemia. Cancer 98 (12):2657-63. doi: 10.1002/cncr.11871
66. Lin TS, et al.: Consolidation therapy with subcutaneous (SC) alemtuzumab results in severe infectious toxicity in previously untreated CLL patients who achieve a complete response (CR) after fludarabine and rituximab (FR) induction therapy: Interim safety analysis of the CALGB study 10101. ASH Annl Meet Abstr 110(11):755
67. Keating, M.J., et al. 1998 Long-term follow-up of patients with chronic lymphocytic leukemia (CLL) receiving fludarabine regimens as initial therapy. Blood 92(4):1165-71.
68. Keating, M.J., et al. 2002 Results of first salvage therapy for patients refractory to a fludarabine regimen in chronic lymphocytic leukemia. Leuk Lymphoma. 43(9):1755-62. doi: 10.1080/1042819021000006547
69. Montserrat, E., et al. 1996 Fludarabine in resistant or relapsing B-cell chronic lymphocytic leukemia: The Spanish Group experience. Leuk Lymphoma 21 (5-6):467-72. doi: 10.3109/10428199609093445
70. O'Brien, S.M., et al. 2001 Results of the fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukemia. J Clin Oncol 19(5):1414-20.
71. Wierda, W., et al. 2005 Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia. J Clin Oncol 23(18):4070-8. doi: 10.1200/ JCO.2005.12.516
72. Bosch, F., et al. 2002 Fludarabine, cyclophosphamide and mitoxantrone in the treatment of resistant or relapsed chronic lymphocytic leukaemia. Br J Haematol 119(4):976-84. doi: 10.1046/j.1365-2141.2002.03959.x
73. Hendry, L., et al. 2004 Fludarabine, cyclophosphamide and mitoxantrone in relapsed or refractory chronic lymphocytic leukemia and low grade non-Hodgkin's lymphoma. Leuk Lymphoma 45(5):945-50. doi: 10.1080/ 10428190310001639489
74. Weiss, M.A., et al. 2003 Pentostatin and cyclophosphamide: An effective new regimen in previously treated patients with chronic lymphocytic leukemia. J Clin Oncol 21(7):1278-84. doi: 10.1200/JCO.2003.08.100
75. Lamanna N, et al.: Pentostatin, cyclophosphamide, and rituximab is an active, well-tolerated regimen for patients with previously treated chronic lymphocytic leukemia. J Clin Oncol 24(10):1575-1581. doi: 10.1200/JCO.2005.04.3836
76. Elter, T., et al. 2005 Fludarabine in combination with alemtuzumab is effective and feasible in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: Results of a phase II trial. J Clin Oncol 23(28):7024-31. doi: 10.1200/JCO.2005.01.9950
77. Faderl, S., et al. 2003 Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignancies. Blood 101(9):3413-5. doi: 10.1182/blood-2002-07-1952
78. Montillo, M., et al. 2007 Combined Fludarabine, Cyclophosphamide, and Alemtuzumab (FCC), an Active Regimen for Treated Patients with Chronic Lymphocytic Leukemia (CLL). ASH Annual Meeting Abstracts 110(11):3133
79. Bergmann, M.A., et al. 2005 Efficacy of bendamustine in patients with relapsed or refractory chronic lymphocytic leukemia: Results of a phase I/II study of the German CLL Study Group. Haematologica 90(10):1357-64.
80. Fischer, K., et al. 2007 Bendamustine in Combination with Rituximab (BR) for Patients with Relapsed Chronic Lymphocytic Leukemia (CLL): A Multicentre Phase II Trial of the German CLL Study Group (GCLLSG). ASH Annual Meeting Abstracts 110(11):3106
81. Jabbour, E., et al. 2004 Stem cell transplantation for chronic lymphocytic leukemia: Should not more patients get a transplant? Bone Marrow Transplant 34(4):289-97. doi: 10.1038/sj.bmt.1704593
82. Marks, D.I., et al. 2002 The toxicity and efficacy of donor lymphocyte infusions given after reduced-intensity conditioning allogeneic stem cell transplantation. Blood 100(9):3108-14. doi: 10.1182/ blood-2002-02-0506
83. Sorror, M.L., et al. 2008 Outcomes after allogeneic hematopoietic cell transplantation with nonmyeloablative or myeloablative conditioning regimens for treatment of lymphoma and chronic lymphocytic leukemia. Blood 111(1):446-52. doi: 10.1182/blood-2007-07-098483
84. Caballero, D., et al. 2005 Allogeneic transplant with reduced intensity conditioning regimens may overcome the poor prognosis of B-cell chronic lymphocytic leukemia with unmutated immunoglobulin variable heavy-chain gene and chromosomal abnormalities (11q- and 17p-). Clin Cancer Res. 11(21):7757-63. doi: 10.1158/1078-0432.CCR-05-0941
85. Sorror ML, et al.: Five-year follow-up of patients with advanced chronic lymphocytic leukemia treated with allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. J Clin Oncol, 2008, 26(30):4912-4920
86. Kahl, C., et al. 2007 Relapse risk in patients with malignant diseases given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. Blood 110(7):2744-8. doi: 10.1182/ blood-2007-03-078592
87. Schetelig J, et al.: Allogeneic hematopoietic stem-cell transplantation for chronic lymphocytic leukemia with 17p deletion: A retrospective European group for blood and marrow transplantation analysis. J Clin Oncol, 2008, 26(31):5094-5100
88. Dreger, P., et al. 2007 Indications for allogeneic stem cell transplantation in chronic lymphocytic leukemia: The EBMT transplant consensus. Leukemia 21(1):12-7. doi: 10.1038/sj.leu.2404441
89. O'Brien, S.M., et al. 2005 Phase I to II multicenter study of oblimersen sodium, a Bcl-2 antisense oligonucleotide, in patients with advanced chronic lymphocytic leukemia. J Clin Oncol 23(30):7697-702. doi: 10.1200/ JCO.2005.02.4364
90. O'Brien, S., et al. 2007 Randomized phase III trial of fludarabine plus cyclophosphamide with or without oblimersen sodium (Bcl-2 antisense) in patients with relapsed or refractory chronic lymphocytic leukemia. J Clin Oncol 25(9):1114-20. doi: 10.1200/JCO.2006.07.1191
91. Chanan-Khan, A., et al. 2006 Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study. J Clin Oncol 24(34):5343-9. doi: 10.1200/ JCO.2005.05.0401
92. Ferrajoli, A., et al. 2008 Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia. Blood 111(11):5291-7. doi: 10.1182/blood-2007-12-130120
93. Moutouh-de Parseval LA, et al.: Tumor lysis syndrome/tumor flare reaction in lenalidomide-treated chronic lymphocytic leukemia. J Clin Oncol 2007,25(31):5047. doi: 10.1200/JCO.2007.14.2141
94. Andritsos, L.A., et al. 2008 Higher doses of lenalidomide are associated with unacceptable toxicity including life-threatening tumor flare in patients with chronic lymphocytic leukemia. J Clin Oncol 26(15):2519-25. doi: 10.1200/JCO.2007.13.9709
95. Lin TS: Wenalidomide: what is the right dose in CLL? Blood 2008, 111(11):5268. doi: 10.1182/blood-2008-03-146878
96. Byrd, J.C., et al. 2007 Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia. Blood 109(2):399-404. doi: 10.1182/blood-2006-05-020735
97. Byrd, J.C., et al. 2006 Comparison of Results from a Phase 1/2 Study of Lumiliximab (Anti-CD23) in Combination with FCR for Patients with Relapsed CLL with Published FCR Results. ASH Annual Meeting Abstracts 108(11):32
98. Coiffier, B., et al. 2008 Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: A phase 1-2 study. Blood 111(3):1094-100. doi: 10.1182/blood-2007-09-111781
99. Wilson WH, et al.: A phase 1 study evaluating the safety, pharmacokinetics, and efficacy of ABT-263 in subjects with refractory or relapsed lymphoid malignancies. J Clin Oncol (Meet Abstr) 2008, 26 (15 suppl):8511